StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
6039.T$948.00+1.28%
Fair $948.00+0.0%

6039.T

Japan Animal Referral Medical Center Co., Ltd.

Consumer Cyclical / Personal ServicesTokyo

$948.00

+12.00 (+1.28%)

Fairly Valued+0.0%Fair Value $948.00Fund rank 23/100 · Data gapFallback financials|
SA 45/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $69.0M · quality 35.3/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 15/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

45/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 6039.TLocal privado en este navegador · Japan Animal Referral Medical Center Co., Ltd.
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$12.3B

P/E

17.7x

↑

EV/EBITDA

11.1x

↑

ROE

12.6%

↑

Gross Margin

34.7%

↑

Debt/Equity

0.84

↑
52-Week Range$948
$477$1605

TradingView lightweight chart

6039.T price, volumen y niveles de valoración

Último $948.00Periodo +189.0%
Fair value: $948.00

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+21.0%

FCF CAGR

—

FCF margin

7.7%

FCF / Net income

0.78x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $5.28B · net income $521.0M · FCF $408.7M

2022-FY → 2025-FY

Gross margin

34.7%-2.4% pts

Operating margin

13.7%-1.1% pts

Net margin

9.9%+0.2% pts

FCF margin

7.7%+9.2% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$5.28B$5.28B$4.27B$3.87B$2.98B
Net Income$521.0M$521.0M$337.2M$380.7M$286.9M
EBITDA$1.32B$1.32B$974.6M$963.4M$677.0M
EPS40.1740.1724.2530.6423.60
Gross Margin34.7%34.7%34.3%37.3%37.1%
Operating Margin13.7%13.7%11.6%15.0%14.7%
Net Margin9.9%9.9%7.9%9.8%9.6%
Balance Sheet
Debt/Equity0.840.841.011.071.56
Current Ratio0.560.56———
Cash Flow
Free Cash Flow$408.7M$408.7M$-155.4M$69.0M$-44.4M
Returns
ROE12.6%12.6%8.8%10.3%11.4%
Valuation
P/E17.7417.7416.0211.8515.31
EV/EBITDA11.1311.138.136.8210.70
P/B2.962.961.421.221.75
Growth & Yield
Revenue Growth23.6%23.6%10.3%30.0%—
EPS Growth65.7%65.7%-20.8%29.8%—
Dividend Yield2.7%2.7%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

27.9%

muy exigente

EPS terminal req.

$84.12

Spread vs growth

37.7%

5Y implied EPS CAGR

20.4%

exigente

EPS terminal req.

$101.78

Spread vs growth

45.2%

10Y implied EPS CAGR

15.1%

exigente

EPS terminal req.

$163.92

Spread vs growth

50.6%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total +94.6%

Total return

+94.6%

Start / end P/E

20.4x → 23.6x

EPS bridge

24.25 → 40.17

Residual

+10.4%

EPS growth+65.7%
Multiple rerating+15.8%
Dividend+2.7%
Residual / FX / buybacks / cross-term+10.4%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.